On World Cancer Day 2026, GLIOMATCH highlights the importance of placing patient perspectives at the heart of cancer research, particularly for glioblastoma, one of the most aggressive and difficult-to-treat brain tumours.
Patient voices shaping innovation in glioblastoma research
GLIOMATCH project partner Cancer Patients Europe (CPE) conducted a Europe-wide survey among people living with glioblastoma, as well as relatives and carers, to explore expectations, concerns and information needs related to innovative therapies, with a specific focus on immunotherapy. The CPE team has summarised the key results below.
The survey results show that survival remains the primary treatment priority for 62 percent of respondents, while quality of life is a critical consideration for one in three. Although 93 percent of respondents said they would be extremely or somewhat willing to use immunotherapy if it offered an improved prognosis, their main concerns relate to potential side effects and the impact on daily life rather than cost.
Interest in clinical research is high, with 82 percent of respondents indicating they would be very or somewhat likely to participate in an immunotherapy clinical trial. However, many also reported limited understanding of the risks and benefits involved, underlining the need for clearer communication and better access to information.
